Ovarian Cancer IMPACT Act
- Sponsor
- Rep. DeLauro, Rosa L. [D-CT-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 24, 2026
Bottom line
The Ovarian Cancer IMPACT Act seeks to improve ovarian cancer outcomes by increasing awareness, expanding access to genetic testing and counseling, and mandating insurance coverage for these services and risk-reducing interventions, particularly for high-risk and underserved populations.
What it actually does
This bill, the Ovarian Cancer IMPACT Act, aims to enhance federal efforts against ovarian cancer. It reauthorizes and expands "Johanna's Law" to include enhanced outreach, education, and demonstration projects for hereditary cancer risk assessment and genetic testing. Crucially, it mandates that group health plans and health insurance issuers provide coverage for genetic counseling, multi-gene panel testing, and risk-reducing interventions for individuals at elevated hereditary risk of ovarian cancer. It also expands rural access to ovarian cancer care services.
Proponents argue
Proponents argue that this bill is a critical step towards reducing the high mortality rate of ovarian cancer by facilitating earlier detection and personalized prevention strategies. They emphasize that expanding access to genetic testing and counseling, especially for hereditary cancer syndromes, will empower individuals and their healthcare providers to make informed decisions about risk reduction and treatment. Supporters also highlight the importance of addressing disparities in care for rural and medically underserved communities.
Opponents contend
Potential opponents, particularly some health insurance industry groups, might raise concerns about the mandated coverage provisions, arguing that they could increase healthcare premiums or administrative burdens. They might contend that such mandates interfere with market-based approaches to healthcare coverage and could lead to over-utilization of certain services without clear evidence of cost-effectiveness across all populations.
The bill is relatively short and its core provisions are clearly laid out, making it accessible for a reader to understand its main impacts within a reasonable timeframe.
Section 3
Enhanced Ovarian Cancer Awareness and Genetic Risk Assessment
This section reauthorizes and significantly expands "Johanna's Law," a national public awareness campaign for ovarian cancer. It directs the Secretary of Health and Human Services to coordinate with HRSA and NCI to develop culturally appropriate educational materials, conduct targeted outreach to high-risk and underserved populations, promote awareness of hereditary cancer syndromes (like HBOC and Lynch syndrome), and disseminate information on insurance coverage for genetic services. It also mandates demonstration projects to test outreach strategies and identify barriers to care, with a preference for projects serving rural or medically underserved areas.
Supporters argue
Supporters argue that enhancing Johanna's Law will directly address critical gaps in public and provider awareness, leading to earlier diagnosis and better outcomes. The focus on hereditary cancer syndromes and underserved populations ensures that those most at risk receive the information and resources needed for prevention and early intervention.
Critics contend
No specific opposition is typically raised against public health awareness campaigns, though some might question the efficiency or effectiveness of specific outreach methods or the overall budget allocation compared to other public health priorities.
Tradeoffs
The primary tension is ensuring that the expanded awareness efforts translate into tangible improvements in access and outcomes, rather than simply increasing demand for services that may still be inaccessible to some.
Section 4
Expanding Rural Health Care Services for Ovarian Cancer
This section amends existing Public Health Service Act programs to specifically include ovarian cancer care. It expands the scope of Rural Health Care Services Outreach Grants to cover ovarian cancer prevention, diagnosis, treatment, survivorship services, hereditary cancer risk assessment, genetic counseling, and care coordination in rural and Tribal communities. It also adds ovarian cancer to the list of conditions addressed by the Expanding Capacity for Health Outcomes (ECHO) program, which uses telehealth to connect specialists with primary care providers.
Section 5
Insurance Coverage for Ovarian Cancer Genetic Services and Prevention
This section mandates that group health plans and health insurance issuers provide coverage for genetic counseling and testing for individuals with a personal history of ovarian or endometrial cancer, or a family history indicative of hereditary ovarian cancer or Lynch syndrome. It specifies the scope of testing to include mutations in BRCA1/2, Lynch syndrome genes, and other relevant genes (BRIP1, RAD51C, RAD51D), adhering to evidence-based clinical guidelines. Furthermore, it requires coverage for evidence-based early detection, hereditary cancer risk management, risk-reducing surgeries (like opportunistic salpingectomy), and other interventions for individuals identified at elevated hereditary risk, regardless of a personal cancer history. This mandate also applies to grandfathered health plans.
Requires the national campaign to disseminate information for patients and providers on evidence-based ovarian cancer risk-reduction strategies, specifically mentioning "opportunistic salpingectomy and the circumstances in which such an intervention may be appropriate."
Section 3(1)(D)(vi)
Why it matters:This is standard legislative practice for detailing the scope of a program's activities. It ensures specific, evidence-based practices are included without elevating them to standalone provisions.
Case for: Proponents would argue that including opportunistic salpingectomy (removal of fallopian tubes during other pelvic surgeries) as a risk-reduction strategy is a crucial, evidence-based intervention that can significantly lower ovarian cancer risk, especially for those at high risk, and should be part of public and provider education.
Case against: Critics might argue that promoting a surgical intervention, even a risk-reducing one, within a public awareness campaign could be seen as overly prescriptive or potentially lead to unnecessary procedures if not carefully communicated. However, the bill specifies "circumstances in which such an intervention may be appropriate," mitigating this concern.
Estimated impact: Potentially significant impact on ovarian cancer incidence if awareness leads to increased adoption of this risk-reducing procedure among eligible individuals.
States that in the case of conflicting guidelines developed by more than one nationally recognized oncology professional organization regarding genetic testing scope, "the least restrictive of such guidelines shall apply."
Section 5(a)(3)
Why it matters:This is a common legislative technique to resolve potential conflicts in clinical guidance, ensuring broad access to services. It's a technical detail rather than a primary policy statement.
Case for: Proponents would argue this ensures maximum patient access to necessary genetic testing by preventing insurers from selectively adopting the most restrictive guidelines to limit coverage. It prioritizes patient care over potential cost savings from narrower criteria.
Case against: Some insurers might argue that this provision could lead to unnecessary testing if the "least restrictive" guideline is overly broad or not fully aligned with the most current consensus on cost-effectiveness, potentially increasing healthcare costs.
Estimated impact: Ensures broader coverage for genetic testing than might otherwise occur if insurers could choose more restrictive guidelines.